Central sleep apnoea
ventilatory control · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Central sleep apnoea reflects loss of ventilatory drive rather than upper-airway collapse, causing repetitive apnoeas without respiratory effort. Common causes include heart failure (Cheyne-Stokes respiration), opioids, high altitude and treatment-emergent central apnoea on CPAP.
Red flags
- Decompensated heart failure
- Opioid overdose risk / respiratory depression
- Severe nocturnal hypoxaemia or hypercapnia
- New focal neurology (central cause)
Assessment
Differential diagnosis
- Obstructive sleep apnoea
- Cheyne-Stokes respiration from heart failure
- Opioid-induced central apnoea
- Treatment-emergent central apnoea
- Hypoventilation syndromes
- Idiopathic central apnoea
Investigations
- Full polysomnography differentiating central from obstructive events
- Echocardiogram and cardiac assessment (ejection fraction)
- Medication review (opioids, methadone)
- Arterial/venous blood gas to assess CO2 and acid-base
- Overnight oximetry/capnography
- Assess for underlying neurological disease where indicated
Management
- Confirm predominance of central (effortless) events on polysomnography
- Identify the underlying cause: heart failure, opioids, altitude, stroke or CPAP-emergent
- Optimise treatment of underlying heart failure (guideline-directed medical therapy)
- Reduce or rationalise opioids and other respiratory depressants where possible
- Trial positive-airway-pressure therapy and distinguish persistent from treatment-emergent central events
- Avoid adaptive servo-ventilation in symptomatic heart failure with reduced ejection fraction (harm signal)
- Consider adaptive servo-ventilation for non-heart-failure or idiopathic central apnoea
- Use supplemental oxygen or CO2-stabilising strategies where appropriate
- Consider phrenic-nerve stimulation in selected patients
- Follow up with repeat sleep study to confirm control and monitor symptoms
Drugs & doses
Supplemental oxygen titrated to abolish central events in selected cases
Acetazolamide 250-500 mg PO at night (respiratory stimulant, selected cases)
Optimise heart-failure therapy (ACE inhibitor/ARNI, beta-blocker, diuretic, SGLT2 inhibitor)
Reduce opioid dose / rotate agents where clinically possible
Disposition
Sleep and cardiology joint management; device therapy via sleep service; treat the underlying driver.
Complications & pitfalls
- Worsening heart failure outcomes
- Daytime sleepiness and reduced quality of life
- Arrhythmia
- Nocturnal hypoxaemia
Exam pearls
- Adaptive servo-ventilation is contraindicated in symptomatic HFrEF (LVEF <=45%) due to increased mortality
- Cheyne-Stokes respiration is a marker of heart-failure severity — optimise the heart first
- Treatment-emergent central apnoea on CPAP often resolves over weeks with continued therapy
- Review opioids before adding device therapy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.